Clifford Chance

Clifford Chance's Moscow office has advised Pfizer on its award winning long term strategic collaboration with Russian pharmaceutical company NovaMedica

Clifford Chance's Moscow office has advised Pfizer on its award winning long term strategic collaboration with Russian pharmaceutical company NovaMedica.

The collaboration involves Pfizer providing finance and technology to NovaMedica for the construction of a new production facility in Russia. The medicines licensed and manufactured under the collaboration will be sold by Pfizer and NovaMedica in Russia and the CIS. The collaboration is driven by the Russian government's "localisation" policy for the pharmaceutical sector, through which medicines manufactured in Russia are preferred in tenders for medicines for the public health service.
NovaMedica's current shareholders are Russian government-backed technology fund RUSNANO and U.S. healthcare venture capital fund Domain Associates. The collaboration was recently voted "deal of the year" by industry peers at an annual Russian pharmaceutical industry awards ceremony (the "Platinum Ounce" awards).
The Clifford Chance team in Moscow was led by partner Torsten Syrbe and senior associate Andrew Robinson. Pfizer's in-house legal team was led by Karen Saah in New York, with support from Lilia Danilova in Moscow. The cross-practice team in Clifford Chance's Moscow office also included senior associates Ekaterina Sharapova, Ekaterina Matveychuk, Michael Anderson, Maria Chivragova, Sardaana Nogovitsyna, Dmitry Malukevich, Vitaly Koloskov, Olga Mizikova and Kamilla Shikhametova, associates Ilya Stekunov and Ani Tangyan and trainee Anna Semenova.